- The first patient has been dosed in a Phase 1 clinical trial evaluating Ocular Therapeutix's (NASDAQ:OCUL +0.5%) OTK-TKI (tyrosine kinase inhibitor implant) in patients with wet age-related macular degeneration (wet AMD).
- The primary objective is safety. The secondary objective is tolerability (maximum tolerated dose). The estimated completion date is May 2020.
- OTX-TKI is a bioresorbable hydrogel formulated with tyrosine kinase inhibitor (TKI) particles in an injectable fiber that is delivered to the back of the eye via a small-gauge needle. It is designed to deliver the drug for up to nine months, significantly longer than the one-to-two-month frequency of standard-of-care intravitreal treatments.